Lixte Biotechnology Holdings, Inc.
LIXT
$4.20
$0.143.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.98M | -775.70K | -709.60K | -617.70K | -986.00K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.00M | 268.00K | 99.70K | 78.00K | 106.80K |
| Change in Net Operating Assets | 49.40K | 20.20K | 41.30K | -59.00K | -78.40K |
| Cash from Operations | -926.80K | -487.50K | -568.50K | -598.70K | -957.60K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.64M | -- | -- | -- | -- |
| Cash from Investing | -2.64M | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.55M | 0.00 | 914.20K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 10.00K | -10.00K | -- | -- | -- |
| Cash from Financing | 5.56M | -10.00K | 914.20K | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.00M | -497.50K | 345.70K | -598.70K | -957.60K |